significantTreatment update
Daratumumab emerging as treatment option for relapsed POEMS
POEMS Syndrome →Summary
Anti-CD38 monoclonal antibody daratumumab, alone or in combination regimens, is being explored for relapsed/refractory POEMS syndrome. Early case series and retrospective data show promising hematologic and VEGF responses, particularly in patients who have failed prior lines of therapy including transplant.
More from POEMS Syndrome
significantDiagnostic advance
VEGF validated as reliable response biomarker across treatment modalities
incrementalTreatment update
Improved transplant outcomes in the modern era
incrementalTreatment update
Lenalidomide plus dexamethasone long-term data confirm durable responses
significantNew research
Single-cell analysis reframes VEGF pathogenesis: plasma cells produce IL-6, not VEGF
ID: poems-syndrome-update-0Type: treatment_updateImpact: significant